HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its ...

Along with its gene editing therapy Casgevy, Vertex is offering fertility preservation support for its patients—a program ...

HHS is asking the court to affirm its Office of Inspector General's finding that paying for fertility services would run ...

The S&P 500’s health care sector (NYSEARCA:XLV), holding a weightage of 12.12% in the S&P 500 index, saw a fall of 10.2% in ...

Vertex has appointed a new commercial head for ex-US activites, as the company aims to resolve its two-year row with UK health officials over the price of its cystic fibrosis drugs.

Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotechnology company with a strong track record of success in developing ...

and Vertex’s chief scientific officer David Altshuler has joined the UK firm’s board. Humana to invest in digital health US health firm Humana is to expand its capability in technology ...

ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth quarter 2024 ...

Vertex Pharmaceuticals has a new drug called suzetrigine that it says is nonaddictive and would offer an alternative to painkillers such as oxycodone. The company’s application is pending before the ...

Vertex Pharmaceuticals Inc. will work with a Watertown biotech on new gene-editing therapies for people with sickle cell disease and transfusion-dependent beta thalassemia.

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $416.96, moving -1.72% from the previous trading session.